Al Mansour Pharmaceuticals (IMAP)

ISX

Currency in IQD

2.390

+0.030(+1.27%)

Closed·09/07

Fair Value

Unlock Value

Day's Range

2.300

2.390

52 wk Range

1.850

2.800

Al Mansour Pharma (IMAP) Income Statement & Profits

Assess the Al Mansour Pharma Income Statement (earnings report), showing the company's financial performance from operating and non operating activities such as revenue, expenses and income. Check assets and liabilities, diluted earnings per share (EPS), and net income after taxes for the last 4 periods (either quarterly or annually).

Investors who need greater depth or who want to customise how data is presented to fit their own investment styles are able to do so via their very own InvestingPro account.

Period Ending:

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

2024

31/12

Total Revenues

aa.aa

848.79

32.5

1,731.74

4,143.52

Total Revenues Growth

aa.aa

+88.85%

-96.17%

+139.27%

Cost Of Revenues

aa.aa

989.62

283.08

1,634.29

2,904.79

Gross Profit

aa.aa

-140.83

-250.58

97.45

1,238.73

Gross Profit Growth

aa.aa

+82.89%

-77.93%

+1,171.08%

Gross Profit Margin %

aa.aa

-16.59%

-771%

5.63%

29.9%

Other Operating Expenses, Total

aa.aa

85.24

5.17

706.69

214.31

427.22

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-36.43%	-93.94%	+13,575.86%	-69.67%	+99.35%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	109.96	27.88	706.69	214.31	427.22
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-24.72	-22.72	-	-	-

Operating Income

aa.aa

-226.07

-255.75

-706.69

-116.86

811.51

Operating Income Growth

aa.aa

+76.39%

-13.13%

-176.32%

+83.46%

+794.46%

EBIT Margin %

aa.aa

-26.63%

-786.9%

-6.75%

19.59%

Net Interest Expenses

aa.aa

194.47

12.71

Net Interest Expenses Growth

aa.aa

-93.46%

Interest Expense, Total

aa.aa

Interest And Investment Income

aa.aa

194.47

12.71

Other Non Operating Expenses, Total

aa.aa

46.61

11.58

28.71

EBT, Excl. Unusual Items

aa.aa

-179.46

-255.75

-706.69

89.2

852.93

Gain (Loss) On Sale Of Assets

aa.aa

Other Unusual Items, Total

aa.aa

EBT, Incl. Unusual Items

aa.aa

-179.46

-255.75

-706.69

89.2

852.93

EBT, Incl. Unusual Items Growth

aa.aa

+90.85%

-42.51%

-176.32%

+112.62%

+856.24%

EBT, Incl. Unusual Items Margin

aa.aa

-21.14%

-786.9%

5.15%

20.58%

Income Tax Expense

aa.aa

106.87

129.39

93.03

43.09

76.95

Net Income to Company

aa.aa

-286.33

-385.13

-799.72

46.11

775.98

Minority Interest

aa.aa

Net Income

aa.aa

-286.33

-385.13

-799.72

46.11

775.98

Net Income Growth

aa.aa

+85.39%

-34.51%

-107.65%

+105.77%

+1,583.03%

Net Income Margin %

aa.aa

-33.73%

-1,185%

2.66%

18.73%

Preferred Dividend and Other Adjustments

aa.aa

Net Income to Common Excl. Extra Items

aa.aa

-286.33

-385.13

-799.72

46.11

775.98

Basic EPS - Continuing Operations

aa.aa

-0.04

-0.06

-0.05

0.05

Basic EPS - Continuing Operations Growth

aa.aa

+85.4%

-34.51%

+16.04%

+105.76%

+1,583.37%

Diluted EPS - Continuing Operations

aa.aa

-0.04

-0.06

-0.05

0.05

Diluted EPS - Continuing Operations Growth

aa.aa

+85.4%

-34.51%

+16.04%

+105.76%

+1,583.37%

Basic Weighted Average Shares Outstanding

aa.aa

6,469.27

16,000

Diluted Weighted Average Shares Outstanding

aa.aa

6,469.27

16,000

Dividend Per Share

aa.aa

Dividend Per Share Growth

aa.aa

EBITDA

aa.aa

29.14

-238.54

-564.2

-9.49

881.83

EBITDA Growth

aa.aa

+103.77%

-918.7%

-136.52%

+98.32%

+9,388.78%

EBITDA Margin %

aa.aa

3.43%

-733.97%

-0.55%

21.28%

EBIT

aa.aa

-226.07

-255.75

-706.69

-116.86

811.51

* In Millions of IQD (except for per share items)

FTSE 100

8,975.66

+108.64

+1.23%

DAX

24,456.81

-92.75

-0.38%

Euro Stoxx 50

5,440.75

-4.90

-0.09%

S&P 500

6,280.39

+17.13

+0.27%

Nikkei 225

39,646.36

-174.92

-0.44%

Dow Jones

44,650.70

+192.40

+0.43%

FTSE 100 Futures

8,996.00

+7.2

+0.08%

Market Movers

Name	Last	Chg. %	Vol.
Barclays	343.65	+1.18%	55.68M
NatWest Group	500.00	+0.48%	32.21M
Rolls-Royce Holdings	975.40	-0.91%	17.49M
British American Tobacco	3,707.0	+3.00%	6.97M
Shell	2,658.0	+1.18%	5.99M
Rio Tinto PLC	4,447.5	+4.00%	5.53M
AstraZeneca	10,626.0	+2.55%	1.48M

Name	Last	Chg. %	Vol.
Inteliqo	0.03	+400.99%	0.00
TechFinancials	0.004	+116.22%	0.00
Futura	11.40	+44.85%	5.65M
Gl Events	28.20	+35.25%	0.00
Gowin New Energy	0.0001	+33.33%	0.00
Norman Broadbent	190.00	+31.03%	23.42K
capAI	0.48	+30.14%	218.62M

Name	Last	Chg. %	Vol.
Tamar Minerals	0.002	-94.29%	0.00
Good Life Plus	0.01	-65.95%	0.00
Carlo Gavazzi Holding AG	190.50	-41.92%	0.00
ChallengerX plc	0.25	-37.50%	400.00K
Indus Gas	11.70	-35.89%	3.27M
Schweizerische Nationalbank	3,310.00	-27.41%	0.00
Wolfspeed	1.62	-24.30%	2.46M

Trending Stocks

Name	Last	Chg. %	Vol.
Rolls-Royce Holdings	975.40	-0.91%	17.49M
Glencore	309.95	+3.94%	37.67M
Wizz Air Holdings	1,044.0	-0.38%	1.50M
Rio Tinto PLC	4,447.5	+4.00%	5.53M
Premier African Minerals	0.0220	-21.99%	6.17B

Most Undervalued Stocks

Name	Last	Upside	Fair Value
Aaaa A A Aa Aaaa Aa	2,059.0	+50.11%	3,090.76
Aaaa Aa A	1,454.50	+40.99%	2,050.70
Aaaaaaa	4,447.5	+33.46%	5,935.63
A Aaaaa Aaaa	154.65	+28.12%	198.14
A Aaaaaaaaaa Aaaaaa	10,626.0	+22.78%	13,046.60
Aaaaaaaaaaa	388.75	+18.11%	459.15
A Aaa Aa	1,948.0	+16.15%	2,262.60

Name	Last	Upside	Fair Value
Aaaa A A Aa Aaaa Aa	2,059.0	+50.11%	3,090.76
Aaaa Aa A	1,454.50	+40.99%	2,050.70
Aaaaaaa	4,447.5	+33.46%	5,935.63
A Aaaaa Aaaa	154.65	+28.12%	198.14
A Aaaaaaaaaa Aaaaaa	10,626.0	+22.78%	13,046.60
Aaaaaaaaaaa	388.75	+18.11%	459.15
A Aaa Aa	1,948.0	+16.15%	2,262.60

See full list

Install Our AppScan QR code to install app

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Popular Searches

Please try another search

Al Mansour Pharmaceuticals (IMAP)

Al Mansour Pharma (IMAP) Income Statement & Profits

Trending Stocks